{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:52:00Z","timestamp":1789750320816,"version":"4.0.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Department of Defense Clinical Trial Award","award":["PR181960"],"award-info":[{"award-number":["PR181960"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We tested whether proton pump inhibitors (PPIs) are associated with enteric infections among those with inflammatory bowel disease (IBD), after adequately accounting for baseline differences between PPI users and nonusers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a self-controlled case series, with each patient serving as their own control. Ambulatory patients with IBD were included if they were tested for enteric infection by multiplex polymerase chain reaction testing panel (GIPCR) and\/or Clostridoides difficile toxin PCR from 2015 to 2019 and received PPIs for some but not all of this period. Rates of enteric infections were compared between the PPI-exposed period vs pre- and post-PPI periods identical in duration to the exposed period. Conditional Poisson regression was used to adjust for time-varying factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred twenty-one IBD patients were included (49% ulcerative colitis, 46% Crohn\u2019s disease, and 5% indeterminate colitis). The median PPI duration was 7 months (interquartile range 4 to 11 months). A total of 25 (11%) patients had a positive GIPCR or C. difficile test in the PPI period, 9 (4%) in the pre-PPI period, and 8 (4%) in the post-PPI period. Observed incidence rates for enteric infections were 2.5, 7.4, and 2.2 per 100 person years for the pre-PPI, PPI, and post-PPI periods, respectively (adjusted incidence rate ratios, 2.8; 95% confidence interval [CI] 1.3-6.0) for PPI vs pre-PPI and 2.9 (95% CI, 1.3-6.4) for PPI vs post-PPI). The adjusted absolute excess risk associated with PPIs was 4.9 infections per 100 person years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Proton pump inhibitors were associated with a 3-fold increased risk for enteric infection among those with IBD but had a modest absolute risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad035","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T18:15:37Z","timestamp":1678817737000},"page":"38-44","source":"Crossref","is-referenced-by-count":11,"title":["Proton pump Inhibitors and Risk of Enteric Infection in Inflammatory Bowel Disease: A Self-controlled Case Series"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-7388","authenticated-orcid":false,"given":"Sanskriti","family":"Varma","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Columbia Vagelos College of Physicians and Surgeons , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[{"name":"Biomedical Informatics, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Freedberg","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"5","key":"2024102814504033700_CIT0001","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","article-title":"Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection","volume":"175","author":"McDonald","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"2024102814504033700_CIT0002","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s10620-015-3642-8","article-title":"The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study","volume":"60","author":"Kelly","year":"2015","journal-title":"Dig Dis Sci."},{"issue":"9","key":"2024102814504033700_CIT0003","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2024102814504033700_CIT0004","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis","volume":"107","author":"Janarthanan","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2024102814504033700_CIT0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology."},{"issue":"8","key":"2024102814504033700_CIT0006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11894-017-0577-6","article-title":"The gastric and intestinal microbiome: role of proton pump inhibitors","volume":"19","author":"Minalyan","year":"2017","journal-title":"Curr Gastroenterol Rep."},{"issue":"5","key":"2024102814504033700_CIT0007","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/ajg.2016.600","article-title":"Proton pump inhibitors and Clostridium difficile infection","volume":"112","author":"Goyal","year":"2017","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"12","key":"2024102814504033700_CIT0008","doi-asserted-by":"crossref","first-page":"e1084","DOI":"10.1093\/cid\/ciaa1857","article-title":"Proton-pump inhibitor use and the risk of community-associated clostridium difficile infection","volume":"72","author":"Inghammar","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"35","key":"2024102814504033700_CIT0009","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol."},{"issue":"4","key":"2024102814504033700_CIT0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.gastro.2015.06.043","article-title":"Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial","volume":"149","author":"Freedberg","year":"2015","journal-title":"Gastroenterology."},{"issue":"6","key":"2024102814504033700_CIT0011","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology."},{"issue":"4","key":"2024102814504033700_CIT0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/BOR.0000000000000190","article-title":"The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity","volume":"27","author":"Longman","year":"2015","journal-title":"Curr Opin Rheumatol."},{"issue":"7422","key":"2024102814504033700_CIT0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature."},{"issue":"4","key":"2024102814504033700_CIT0014","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/mi.2017.22","article-title":"Diversity and functions of intestinal mononuclear phagocytes","volume":"10","author":"Joeris","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"5","key":"2024102814504033700_CIT0015","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1053\/j.gastro.2015.08.006","article-title":"Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases","volume":"149","author":"Dubinsky","year":"2015","journal-title":"Gastroenterology."},{"issue":"1","key":"2024102814504033700_CIT0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology."},{"issue":"6","key":"2024102814504033700_CIT0017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology","volume":"275","author":"Hallas","year":"2014","journal-title":"J Intern Med."},{"issue":"12","key":"2024102814504033700_CIT0018","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"2024102814504033700_CIT0019","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"2024102814504033700_CIT0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1503\/cmaj.071812","article-title":"Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection","volume":"179","author":"Dial","year":"2008","journal-title":"CMAJ."},{"issue":"1","key":"2024102814504033700_CIT0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12866-017-1018-2","article-title":"FilmArray GI panel performance for the diagnosis of acute gastroenteritis or hemorragic diarrhea","volume":"17","author":"Piralla","year":"2017","journal-title":"BMC Microbiol."},{"issue":"3","key":"2024102814504033700_CIT0022","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/JCM.02674-14","article-title":"Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis","volume":"53","author":"Buss","year":"2015","journal-title":"J Clin Microbiol."},{"issue":"1","key":"2024102814504033700_CIT0023","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/JCM.00734-09","article-title":"Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile","volume":"48","author":"Larson","year":"2010","journal-title":"J Clin Microbiol."},{"issue":"3","key":"2024102814504033700_CIT0024","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10620-021-06909-3","article-title":"Inappropriateness of proton pump inhibitors after hospital discharge is associated with thirty-day hospital readmission","volume":"67","author":"Blackett","year":"2022","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2024102814504033700_CIT0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455008","article-title":"Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease","volume":"95","author":"Shah","year":"2017","journal-title":"Digestion."},{"issue":"3","key":"2024102814504033700_CIT0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.2012.05173.x","article-title":"Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease","volume":"36","author":"Juillerat","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"2024102814504033700_CIT0027","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1136\/gutjnl-2020-321609","article-title":"The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies","volume":"70","author":"Lu","year":"2021","journal-title":"Gut."},{"issue":"3","key":"2024102814504033700_CIT0028","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","article-title":"Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis","volume":"10","author":"Deshpande","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2024102814504033700_CIT0029","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2024102814504033700_CIT0030","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1053\/j.gastro.2021.08.005","article-title":"Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of 3 prospective cohorts","volume":"161","author":"Xia","year":"2021","journal-title":"Gastroenterology."},{"issue":"7","key":"2024102814504033700_CIT0031","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ajg.2013.30","article-title":"Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data","volume":"108","author":"Brophy","year":"2013","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"2024102814504033700_CIT0032","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/ajg.2013.333","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients","volume":"108","author":"Freedberg","year":"2013","journal-title":"Am J Gastroenterol."},{"issue":"31","key":"2024102814504033700_CIT0033","doi-asserted-by":"crossref","first-page":"17562848211004493","DOI":"10.1177\/17562848211004493","article-title":"The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review","volume":"14","author":"Axelrad","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"2024102814504033700_CIT0034","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s10620-020-06504-y","article-title":"Patients with more severe IBD Get Clostridioides difficile rather than Clostridioides difficile increasing the severity of IBD","volume":"66","author":"Varma","year":"2021","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2024102814504033700_CIT0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024102814504033700_CIT0036","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ibd.22964","article-title":"Clostridium difficile infection in the inflammatory bowel disease patient","volume":"19","author":"Berg","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2024102814504033700_CIT0037","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrgastro.2012.87","article-title":"IBD: poor outcomes after Clostridium difficile infection in IBD","volume":"9","author":"Khanna","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"6","key":"2024102814504033700_CIT0038","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1572-0241.2007.01780.x","article-title":"A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2024102814504033700_CIT0039","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2036.2011.04661.x","article-title":"Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease","volume":"33","author":"Jen","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2024102814504033700_CIT0040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/MIB.0000000000001097","article-title":"Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing","volume":"23","author":"Axelrad","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024102814504033700_CIT0041","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2009.04.001","article-title":"Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis","volume":"137","author":"Gradel","year":"2009","journal-title":"Gastroenterology."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad035\/49523792\/izad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/1\/38\/60143020\/izad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/1\/38\/60143020\/izad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T14:55:26Z","timestamp":1730127326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/1\/38\/7077422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,14]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad035","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,3,14]]}}}